


# PRODUCT INFORMATION



## Gilvocarcin M

Item No. 25762

**CAS Registry No.:** 77879-89-1  
**Formal Name:** 4-(6-deoxy- $\alpha$ -D-galactofuranosyl)-1-hydroxy-10,12-dimethoxy-8-methyl-6H-benzo[d]naphtho[1,2-b]pyran-6-one  
**Synonym:** Antibiotic 1072A  
**MF:** C<sub>26</sub>H<sub>26</sub>O<sub>9</sub>  
**FW:** 482.5  
**Purity:**  $\geq 95\%$   
**Supplied as:** A lyophilized powder  
**Storage:** -20°C  
**Stability:**  $\geq 4$  years  
**Item Origin:** Bacterium/*Streptomyces* sp.



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Gilvocarcin M is supplied as a lyophilized powder. A stock solution may be made by dissolving the gilvocarcin M in the solvent of choice, which should be purged with an inert gas. Gilvocarcin M is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas.

### Description

Gilvocarcin M is an antibiotic originally isolated from *S. gilvotanareus*.<sup>1</sup> It is active against *S. aureus* when used at a concentration of 32  $\mu\text{g/ml}$ .<sup>2</sup> Gilvocarcin M inhibits growth of KB cells ( $\text{IC}_{50} = 0.52 \mu\text{g/ml}$ ) but has no effect on survival in a P388 mouse model of leukemia when used at doses ranging from 25 to 400 mg/kg.<sup>3</sup> Gilvocarcin M intercalates into bacteriophage PM2 DNA.<sup>4</sup> It is toxic to rats with an intravenous  $\text{LD}_{50}$  value of 450 mg/kg.<sup>3</sup>

### References

1. Nakano, H., Matsuda, Y., Ito, K., *et al.* Gilvocarcins, new antitumor antibiotics. 1. Taxonomy, fermentation, isolation and biological activities. *J. Antibiot. (Tokyo)* **34(3)**, 266-270 (1981).
2. Balitz, D.M., O'Herron, F.A., Bush, J., *et al.* Antitumor agents from *Streptomyces anandii*: Gilvocarcins V, M and E. *J. Antibiot. (Tokyo)* **34(12)**, 1544-1555 (1981).
3. Morimoto, M., Okubo, S., Tomita, F., *et al.* Gilvocarcins, new antitumor antibiotics. 3. Antitumor activity. *J. of Antibiot. (Tokyo)* **34(6)**, 701-707 (1981).
4. Tomita, F., Takahashi, K.-I., and Tamaoki, T. Gilvocarcins, new antitumor antibiotics. 4. Mode of action. *J. Antibiot. (Tokyo)* **35(8)**, 1038-1041 (1982).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)